274 related articles for article (PubMed ID: 29879966)
21. Antidiabetic medications use trends in an Andalusian region from 2001 to 2014.
López-Sepúlveda R; García Lirola MÁ; Espínola García E; Jurado Martínez JM; Martín Sances S; Anaya Ordóñez S; Cabeza Barrera J
Prim Care Diabetes; 2017 Jun; 11(3):254-264. PubMed ID: 28126469
[TBL] [Abstract][Full Text] [Related]
22. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
[TBL] [Abstract][Full Text] [Related]
23. [New, expensive antidiabetics for the treatment of type-2 diabetes--pro].
Müller-Wieland D
Dtsch Med Wochenschr; 2010 May; 135(18):922. PubMed ID: 20425678
[No Abstract] [Full Text] [Related]
24. Utilization patterns of insulin for patients with type 2 diabetes from national health insurance claims data in South Korea.
Min KL; Koo H; Choi JJ; Kim DJ; Chang MJ; Han E
PLoS One; 2019; 14(3):e0210159. PubMed ID: 30840630
[TBL] [Abstract][Full Text] [Related]
25. Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea.
Kim JY; Kim SJ; Nam CM; Moon KT; Park EC
Eur J Public Health; 2018 Apr; 28(2):209-214. PubMed ID: 29579210
[TBL] [Abstract][Full Text] [Related]
26. Replacement Effects and Budget Impacts of Insurance Coverage for Sodium-Glucose Co-Transporter-2 Inhibitors on Oral Antidiabetic Drug Utilization.
Chen HY; Chiu PY; Chang CJ; Tsai LL; Huang YL; Hsu JC
Clin Drug Investig; 2018 Dec; 38(12):1125-1133. PubMed ID: 30219950
[TBL] [Abstract][Full Text] [Related]
27. [Prescribing behavior of primary care physicians in diabetes therapy: effect of drug budgeting].
Jünger C; Rathmann W; Giani G
Dtsch Med Wochenschr; 2000 Feb; 125(5):103-9. PubMed ID: 10705882
[TBL] [Abstract][Full Text] [Related]
28. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
29. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis.
Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Whitmire JT; Anderson RT
Curr Med Res Opin; 2004 Oct; 20(10):1633-40. PubMed ID: 15462696
[TBL] [Abstract][Full Text] [Related]
30. The impact of differential cost sharing of prescription drugs on the use of primary care clinics among patients with hypertension or diabetes.
Park E; Kim D; Choi S
Public Health; 2019 Aug; 173():105-111. PubMed ID: 31265939
[TBL] [Abstract][Full Text] [Related]
31. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
32. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
Heo JH; Rascati KL; Lee EK
Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
[TBL] [Abstract][Full Text] [Related]
33. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
34. [Impact of the Pharmaceutical Copayment Reform on the Use of Antidiabetics, Antithrombotics and for Chronic Obstructive Airway Disease Agents, Spain].
Puig-Junoy J; Rodríguez-Feijóo S; González López-Valcárcel B; Gómez-Navarro V
Rev Esp Salud Publica; 2016 Apr; 90():E6. PubMed ID: 27125567
[TBL] [Abstract][Full Text] [Related]
35. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.
Cho MH; Yoo KB; Lee HY; Lee KS; Kwon JA; Han KT; Kim JH; Park EC
Health Policy; 2015 May; 119(5):604-11. PubMed ID: 25630635
[TBL] [Abstract][Full Text] [Related]
36. Public drug expenditure in the Republic of Ireland.
Barry M; Usher C; Tilson L
Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
[TBL] [Abstract][Full Text] [Related]
37. Assessing the effects of drug price reduction policies on older people in Taiwan.
Chu HL; Liu SZ; Romeis JC
Health Serv Manage Res; 2011 Feb; 24(1):1-7. PubMed ID: 21285360
[TBL] [Abstract][Full Text] [Related]
38. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.
Śliwczyński A; Brzozowska M; Jacyna A; Iltchev P; Iwańczuk T; Wierzba W; Marczak M; Orlewska K; Szymański P; Orlewska E
PLoS One; 2017; 12(6):e0178764. PubMed ID: 28582404
[TBL] [Abstract][Full Text] [Related]
39. Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea.
Park CM; Lee KS; Han E; Kim DS
Health Policy; 2016 Jun; 120(6):590-5. PubMed ID: 27241339
[TBL] [Abstract][Full Text] [Related]
40. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.
Chen LC; Schafheutle EI; Noyce PR
Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
